Geode Capital Management: TG Therapeutics TGTX Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 207 M | Compra |
3,703,676
+61,460
| +2% | +USD 3.33 M | 0.01% | 751 |
|
|
2026
Q2 | USD 200 M | Compra |
3,642,216
+142,300
| +4% | +USD 5.82 M | 0.01% | 804 |
|
|
2026
Q1 | USD 116 M | Compra |
3,499,916
+96,050
| +3% | +USD 2.86 M | 0.01% | 990 |
|
|
2025
Q4 | USD 101 M | Venta |
3,403,866
-40,053
| -1% | -USD 1.31 M | 0.01% | 1068 |
|
|
2025
Q3 | USD 125 M | Venta |
3,443,919
-46,538
| -1% | -USD 1.53 M | 0.01% | 935 |
|
|
2025
Q2 | USD 126 M | Compra |
3,490,457
+207,890
| +6% | +USD 7.74 M | 0.01% | 877 |
|
|
2025
Q1 | USD 129 M | Compra |
3,282,567
+89,062
| +3% | +USD 3 M | 0.01% | 823 |
|
|
2024
Q4 | USD 96.1 M | Venta |
3,193,505
-11,723
| -0.4% | -USD 336 k | 0.01% | 1029 |
|
|
2024
Q3 | USD 75 M | Venta |
3,205,228
-1,162
| -0% | -USD 25.4 k | 0.01% | 1187 |
|
|
2024
Q2 | USD 57.1 M | Compra |
3,206,390
+98,946
| +3% | +USD 1.58 M | 0.01% | 1268 |
|
|
2024
Q1 | USD 47.3 M | Compra |
3,107,444
+10,798
| +0.3% | +USD 172 k | ﹤0.01% | 1397 |
|
|
2023
Q4 | USD 52.9 M | Compra |
3,096,646
+162,820
| +6% | +USD 1.89 M | 0.01% | 1315 |
|
|
2023
Q3 | USD 24.5 M | Compra |
2,933,826
+103,237
| +4% | +USD 1.44 M | ﹤0.01% | 1692 |
|
|
2023
Q2 | USD 70.3 M | Compra |
2,830,589
+150,789
| +6% | +USD 3.89 M | 0.01% | 1010 |
|
|
2023
Q1 | USD 40.3 M | Compra |
2,679,800
+93,527
| +4% | +USD 1.42 M | 0.01% | 1340 |
|
|
2022
Q4 | USD 30.6 M | Compra |
2,586,273
+175,834
| +7% | +USD 1.28 M | ﹤0.01% | 1484 |
|
|
2022
Q3 | USD 14.3 M | Compra |
2,410,439
+86,835
| +4% | +USD 570 k | ﹤0.01% | 1989 |
|
|
2022
Q2 | USD 9.9 M | Compra |
2,323,604
+135,133
| +6% | +USD 844 k | ﹤0.01% | 2262 |
|
|
2022
Q1 | USD 20.8 M | Venta |
2,188,471
-121,366
| -5% | -USD 1.4 M | ﹤0.01% | 1878 |
|
|
2021
Q4 | USD 43.9 M | Compra |
2,309,837
+7,459
| +0.3% | +USD 194 k | 0.01% | 1400 |
|
|
2021
Q3 | USD 76.6 M | Compra |
2,302,378
+145,702
| +7% | +USD 4.51 M | 0.01% | 965 |
|
|
2021
Q2 | USD 83.7 M | Compra |
2,156,676
+109,244
| +5% | +USD 4.29 M | 0.01% | 905 |
|
|
2021
Q1 | USD 98.7 M | Compra |
2,047,432
+269,045
| +15% | +USD 12.9 M | 0.02% | 763 |
|
|
2020
Q4 | USD 92.5 M | Compra |
1,778,387
+154,545
| +10% | +USD 5.22 M | 0.02% | 733 |
|
|
2020
Q3 | USD 43.5 M | Compra |
1,623,842
+123,295
| +8% | +USD 2.84 M | 0.01% | 994 |
|
|
2020
Q2 | USD 29.2 M | Compra |
1,500,547
+160,014
| +12% | +USD 2.58 M | 0.01% | 1225 |
|
|
2020
Q1 | USD 13.2 M | Compra |
1,340,533
+239,730
| +22% | +USD 3.03 M | ﹤0.01% | 1565 |
|
|
2019
Q4 | USD 12.2 M | Venta |
1,100,803
-14,542
| -1% | -USD 111 k | ﹤0.01% | 1872 |
|
|
2019
Q3 | USD 6.26 M | Compra |
1,115,345
+80,716
| +8% | +USD 563 k | ﹤0.01% | 2249 |
|
|
2019
Q2 | USD 8.95 M | Compra |
1,034,629
+106,480
| +11% | +USD 805 k | ﹤0.01% | 2032 |
|
|
2019
Q1 | USD 7.46 M | Compra |
928,149
+172,944
| +23% | +USD 935 k | ﹤0.01% | 2092 |
|
|
2018
Q4 | USD 3.1 M | Compra |
755,205
+70,398
| +10% | +USD 350 k | ﹤0.01% | 2512 |
|
|
2018
Q3 | USD 3.83 M | Compra |
684,807
+95,877
| +16% | +USD 1.1 M | ﹤0.01% | 2531 |
|
|
2018
Q2 | USD 7.74 M | Compra |
588,930
+90,679
| +18% | +USD 1.25 M | ﹤0.01% | 2066 |
|
|
2018
Q1 | USD 7.08 M | Compra |
498,251
+35,981
| +8% | +USD 460 k | ﹤0.01% | 2017 |
|
|
2017
Q4 | USD 3.79 M | Compra |
462,270
+8,699
| +2% | +USD 76 k | ﹤0.01% | 2373 |
|
|
2017
Q3 | USD 5.37 M | Compra |
453,571
+22,817
| +5% | +USD 260 k | ﹤0.01% | 2165 |
|
|
2017
Q2 | USD 4.33 M | Compra |
430,754
+68,401
| +19% | +USD 766 k | ﹤0.01% | 2263 |
|
|
2017
Q1 | USD 4.22 M | Compra |
362,353
+70,751
| +24% | +USD 508 k | ﹤0.01% | 2213 |
|
|
2016
Q4 | USD 1.36 M | Compra |
291,602
+9,477
| +3% | +USD 55.6 k | ﹤0.01% | 2845 |
|
|
2016
Q3 | USD 2.18 M | Compra |
282,125
+4,848
| +2% | +USD 31.2 k | ﹤0.01% | 2512 |
|
|
2016
Q2 | USD 1.68 M | Compra |
277,277
+158
| +0.1% | +USD 1.28 k | ﹤0.01% | 2590 |
|
|
2016
Q1 | USD 2.36 M | Compra |
277,119
+25,517
| +10% | +USD 223 k | ﹤0.01% | 2347 |
|
|
2015
Q4 | USD 3 M | Compra |
251,602
+3,986
| +2% | +USD 50.3 k | ﹤0.01% | 2208 |
|
|
2015
Q3 | USD 2.5 M | Compra |
247,616
+2,896
| +1% | +USD 43.2 k | ﹤0.01% | 2289 |
|
|
2015
Q2 | USD 4.06 M | Compra |
244,720
+51,022
| +26% | +USD 808 k | ﹤0.01% | 2050 |
|
|
2015
Q1 | USD 3 M | Compra |
193,698
+9,812
| +5% | +USD 149 k | ﹤0.01% | 2177 |
|
|
2014
Q4 | USD 2.91 M | Compra |
183,886
+7,573
| +4% | +USD 98.6 k | ﹤0.01% | 2173 |
|
|
2014
Q3 | USD 1.88 M | Compra |
176,313
+1,806
| +1% | +USD 16.7 k | ﹤0.01% | 2388 |
|
|
2014
Q2 | USD 1.64 M | Compra |
174,507
+22,340
| +15% | +USD 143 k | ﹤0.01% | 2509 |
|
|
2014
Q1 | USD 1.05 M | Compra |
152,167
+64,460
| +73% | +USD 382 k | ﹤0.01% | 2768 |
|
|
2013
Q4 | USD 342 k | Compra |
87,707
+1,103
| +1% | +USD 4.46 k | ﹤0.01% | 3238 |
|
|
2013
Q3 | USD 441 k | Compra |
86,604
+67,814
| +361% | +USD 415 k | ﹤0.01% | 3009 |
|
|
2013
Q2 | USD 120 k | Compra |
+18,790
| Nuevas | +USD 120 k | ﹤0.01% | 3384 |
|
Otros fondos que tienen TGTX en su portafolio
Posición de Geode Capital Management en TGTX: resumen de T3 2026
Geode Capital Management aumentó su participación en TG Therapeutics (TGTX) en 1.7% durante T3 2026, al comprar aproximadamente USD 3.33 M y elevar la posición a 3,703,676 acciones con un valor de USD 207 M. La posición representa 0.01% del portafolio y ocupa el puesto #751.
Geode Capital Management reportó por primera vez una posición en TGTX en T2 2013 y desde entonces la ha mantenido en 54 trimestres. Al cierre de T3 2026, 455 fondos que sigue Wall St. Rank mantienen una posición en TGTX.
- Al cierre de T3 2026, Geode Capital Management tenía 3,703,676 acciones de TG Therapeutics con un valor de USD 207 M.
- Geode Capital Management compró 61,460 acciones de TG Therapeutics en T3 2026, por un monto estimado de USD 3.33 M.
- TG Therapeutics representó el 0.01% del portafolio de Geode Capital Management en T3 2026 y fue su posición número 751.
- Geode Capital Management reportó por primera vez una posición en TG Therapeutics en T2 2013 y desde entonces la ha mantenido en 54 trimestres.
- Al cierre de T3 2026, 455 fondos que sigue Wall St. Rank tenían TG Therapeutics en su portafolio.
Según el informe 13F de Geode Capital Management correspondiente a T3 2026, presentado el 6 nov 2026.